The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.

The genomic drug developer, which counts GV as an investor, has completed its initial public offering, boosting its size from $180m to $207m.

D1 Capital Partners has led a series E round for Outset Medical, pushing the Baxter-backed dialysis device developer’s overall funding to more than $430m.

Simran Trana, at one point a director of Purdue’s Office of Technology Commercialization has joined the Indiana University Innovation and Commercialization Office as associate vice-president.

Gulf Capital led a round that boosted the Crescent Enterprises-backed medical booking platform's total funding to more than $63m.

Columbia's drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Cox Enterprises formed part of a consortium that provided $126m for Iora Health, a healthcare provider whose investors also include Humana and General Electric.

Illumina Ventures returned to reinvest in a $21.8m round for the DNA-analysis system developer having led its series A round in 2018.

Paris Saclay Seed Fund and all other existing backers returned for the series B round, which additionally attracted Tsinghua University’s TUS Holdings.